Pharma Stability: Insights, Guidelines, and Expertise
Stability data is essential for establishing the shelf life, storage conditions, and quality profile of a drug product. In expedited pathways, regulatory agencies may accept limited real-time data supplemented by accelerated or bridging studies — provided the data is scientifically justified and aligned with ICH and agency-specific expectations.
Click to read the full article.
Discrepancies occur when trends observed in accelerated stability studies do not align with those observed during real-time long-term studies. These can manifest as:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Managing stability studies manually via spreadsheets or isolated databases can result in missed pulls, inconsistent documentation, and non-compliant audit trails. Software solutions eliminate these risks by automating workflows, ensuring centralized data access, and enabling analytics.
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Stability study requirements vary based on the product’s target market, which is classified by climatic zones as defined by WHO and ICH. Emerging markets predominantly fall under the most stringent categories: Zone IVa and Zone IVb.
Click to read the full article.
Matrixing is a statistical design approach where only a selected subset of the total number of possible samples is tested at each scheduled time point. The full set of combinations is still tested over the course of the study, but each specific sample is tested at fewer time points.
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.